An open label dose adjustment and phase II study of E7070 in combination with capecitabine: Part 1: to determine the recommended dose of the combination Part 2: to determine the efficacy of the comb...

Update Il y a 4 ans
Reference: EUCTR2004-002597-33

An open label dose adjustment and phase II study of E7070 in combination with capecitabine: Part 1: to determine the recommended dose of the combination Part 2: to determine the efficacy of the combination in patients with metastatic colorectal cancer (CRC) who are resistant to or unsuitable for treatment with 5-fluorouracil and irinotecan and/or oxaliplatin

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To determine the safety, tolerability and efficacy (in terms of response rate and progression-free survival) of the combination in patients with metastatic CRC resistant to or unsuitable for treatment with 5-fluorouracil and irinotecan and/or oxaliplatin.


Inclusion criteria

  • Metastatic Colorectal Cancer resistant to or unsuitable for treatment with 5-fluorouracil and irinotecan and/or oxaliplatin

Links